Status:
COMPLETED
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
Lead Sponsor:
NEAT ID Foundation
Collaborating Sponsors:
European Commission
PENTA Foundation
Conditions:
Monkeypox
HIV Coinfection
Eligibility:
All Genders
18+ years
Brief Summary
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also a...
Eligibility Criteria
Inclusion
- Diagnosis of MPX was more than 90 days prior to data collection
- Confirmed MPX infection by documented PCR testing of lesions between 1st May 2022 to 1st December 2023
- At least 18 years of age
- Cases (PLWHIV + MPX) i) Documented HIV-1 infection
- Cases (PrEP users + MPX) i) Attended a clinic to receive PrEP
Exclusion
- MPX diagnosed based on clinical criteria only
- MPX diagnosis was within the last 90 days
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 7 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05965427
Start Date
December 1 2023
End Date
May 7 2025
Last Update
August 13 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bichat Claude Bernard
Paris, France
2
Hôpital Pitié-Salpêtrière
Paris, France
3
Euroguidelines
Warsaw, Poland
4
Hospital Clinic de Barcelona
Barcelona, Spain